What are Regeneron's primary product candidates in development?

Regeneron's primary product candidates in clinical development are VEGF Trap (for cancer and eye diseases, Phase I), IL-1 Trap (for rheumatoid arthritis, Phase II), IL-4/13 Trap (for asthma, Phase I), and AXOKINE (for obesity, Phase III).

What is the financial status of Regeneron as of December 31, 2003?

As of December 31, 2003, Regeneron had not generated any product sales and reported a net loss of $107.5 million for the year, contributing to a cumulative loss of $531.5 million since inception. The company held $366.6 million in cash, cash equivalents, and marketable securities, funded primarily through equity offerings and collaboration agreements.

What impact does the termination of the Novartis collaboration have on Regeneron?

Novartis's decision to withdraw from the IL-1 Trap collaboration means Regeneron will need to fund the continued development and potential commercialization of IL-1 Trap without Novartis's support, requiring substantially greater expenditures and potentially delaying the program. However, Novartis remains obligated to fund certain pre-Phase III development expenses during a transition period.

How does Regeneron plan to fund its ongoing research and development activities?

Regeneron's funding strategy relies on equity offerings, revenue from its contract manufacturing agreement with Merck, investment income, and significant funding from its collaborators, including upfront payments, research progress payments, and funding of development expenses under collaboration agreements. The company anticipates substantial ongoing R&D expenses and expects to require additional financing in the future.

REGN 10-K FY2003 Annual Report — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious medical conditions. As of the fiscal year ended December 31, 2003, the company had not yet generated any sales or profits from product commercialization, incurring a cumulative loss of $531.5 million since inception. Its pipeline includes product candidates for cancer, eye diseases, rheumatoid arthritis, allergies, asthma, and obesity. Significant collaborations are in place, notably with Aventis for VEGF Trap and previously with Novartis for IL-1 Trap, which was recently terminated by Novartis. The company's financial strategy relies on equity offerings and collaborator funding, with substantial ongoing investment in research and development expected to continue generating losses for the foreseeable future. The company's primary product candidates are VEGF Trap (in Phase I for cancer and eye diseases), IL-1 Trap (in Phase II for rheumatoid arthritis), IL-4/13 Trap (in Phase I for asthma), and AXOKINE (in Phase III for obesity). The company has developed proprietary technology platforms, including Targeted Genomics, Velocigene, and Designer Protein Therapeutics, to aid in drug discovery and development. Despite significant investment and progress, the company faces substantial risks related to clinical trial outcomes, regulatory approvals, competition, and the need for ongoing financing.

Key Highlights

1Regeneron has a diversified pipeline with product candidates in various stages of clinical development for serious medical conditions, including cancer, eye diseases, rheumatoid arthritis, and obesity.

2The company entered into a significant collaboration with Aventis for VEGF Trap, including an upfront payment and equity investment, with potential for substantial milestone payments.

3Novartis has recently announced its intention to withdraw from the joint development of the IL-1 Trap, impacting future development plans and funding for this candidate.

4As of year-end 2003, Regeneron had not generated product sales, continuing to operate at a net loss and relying on equity financing and collaboration revenue to fund substantial R&D expenses.

5The company possesses proprietary technology platforms (Targeted Genomics, Velocigene, Designer Protein Therapeutics) that are core to its discovery and development strategy.

6Regeneron faces intense competition from larger pharmaceutical and biotechnology companies with greater resources.

7The company has a history of stock issuances to collaborators (Aventis, Novartis, Merck) as part of strategic agreements.

REGENERON PHARMACEUTICALS, INC. Annual Report (Amendment), Year Ended Dec 31, 2003

Summary

Key Highlights

Frequently Asked Questions